AJ Gelderblom
Leiden University Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name AJ Gelderblom as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:42 UTC. Open this list on ClinicalTrials.gov
- N/ANCT05685836 · 89Zr-Bevacizumab PET/CT Imaging in NF2 PatientsLeiden University Medical Center · unknown · Neurofibromatosis 2 · principal investigator
- Ph2NCT03605199 · Denosumab in Subjects With Giant Cell Rich Tumors of BoneLeiden University Medical Center · unknown · Aneurysmal Bone Cysts, Giant Cell Granuloma, Osteoblastoma · principal investigator
- Ph2NCT03083678 · Afatinib in Locally Advanced and Metastatic ChordomaLeiden University Medical Center · completed · Chordoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:42 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:42 UTC. The ranking covers the 200 most relevant of 4 PubMed records, and a shared surname and initials can bring in a namesake. All 4 on PubMed
- 100 citationsRCR 3.2
- Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors.J Clin Oncol · 199926 citationsRCR 0.8
- Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatin.Ann Oncol · 20007 citationsRCR 0.2
- The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP).ESMO Open · 20257 citationsRCR 0.9